GlassScriptPhysician profile
Shailesh R Patel
NPI 1720145246
$5,853.76
in general payments reported to CMS, 2019-2025
32 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $101 · 2021: $426 · 2022: $1,084 · 2023: $1,070 · 2024: $1,515 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,593 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,593.13 |
| Education | $181.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,272.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Harmony Biosciences LLC | $863.43 | 2022-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $685.07 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Genzyme Corporation | $390.69 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.04 | 2019-2025 | Ofev |
| Jazz Pharmaceuticals INC. | $334.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $314.09 | 2021-2024 | Dupixent |
| Insmed, INC. | $282.80 | 2020-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $188.64 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $178.63 | 2022-2024 | Glassia |
| Amgen INC. | $142.19 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $130.05 | 2019-2025 | Prolastin-C Liquid |
| Electromed, INC. | $110.03 | 2019-2025 | Smartvest |
| Pfizer INC. | $109.00 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $59.09 | 2023-2024 | Acthar |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.13 | 2025 | Zepbound |
| Verona Pharma, INC. | $51.25 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $36.65 | 2019 | |
| Phathom Pharmaceuticals, INC. | $34.58 | 2025 | Voquezna |
| Itamar Medical INC | $32.52 | 2024 | Watchpatone |
| Genentech USA, INC. | $27.47 | 2019 | |
| Vifor Pharma, INC. | $27.44 | 2024 | Veltassa |
| Circassia INC. | $25.82 | 2019 | |
| Idorsia Pharmaceuticals US INC | $23.49 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $21.94 | 2023 | Belsomra |
| Axsome Therapeutics, INC. | $21.92 | 2023 | Sunosi |
| United Therapeutics Corporation | $20.98 | 2022 | |
| Mylan Specialty L.P. | $20.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.55 | 2019 | |
| Philips North America LLC | $14.87 | 2021 | |
| Nabriva Therapeutics, Plc | $13.33 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.